Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

Segment information for fiscal year 2020 is as follows (in thousands):

	Year Ended December 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product Revenue	$	30,220	$	—	$	30,220
Research and development revenue	17,886		20,950		38,836
Total revenues	$	48,106	$	20,950	$	69,056
Primary geographical markets:
Americas	$	11,111	$	13,241	$	24,352
EMEA	11,548		7,709		19,257
APAC	25,447		—		25,447
Total revenues	$	48,106	$	20,950	$	69,056

Segment information for fiscal year 2019 is as follows (in thousands):

	Year Ended December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product Revenue	$	29,465	$	—	$	29,465
Research and development revenue	28,691		10,302		38,993
Total revenues	$	58,156	$	10,302	$	68,458
Primary geographical markets:
Americas	$	13,039	$	—	$	13,039
EMEA	26,831		10,302		37,133
APAC	18,286		—		18,286
Total revenues	$	58,156	$	10,302	$	68,458

Segment information for fiscal year 2018 is as follows (in thousands):

	Year Ended December 31, 2018
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product Revenue	$	25,590	$	—	$	25,590
Research and development revenue	21,483		13,521		35,004
Total revenues	$	47,073	$	13,521	$	60,594
Primary geographical markets:
Americas	$	15,332	$	38	$	15,370
EMEA	8,878		13,483		22,361
APAC	22,863		—		22,863
Total revenues	$	47,073	$	13,521	$	60,594

Contract Balances

The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):

	December 31, 2020		December 31, 2019
Contract assets	$	4,526	$	1,027
Unbilled receivables	$	10,942	$	10,099
Contract costs	$	90	$	—
Contract liabilities: deferred revenue	$	4,791	$	2,044

Contract with Customer

We recognized the following revenues (in thousands):

	Year Ended December 31,
Revenue recognized in the period for:	2020		2019
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied	$	57	$	4,567
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	774		1,442
Performance obligations satisfied from new activities in the period - contract revenue	68,225		62,449
Total revenues	$	69,056	$	68,458

Performance Obligation, Expected Timing of Satisfaction

The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands):

	2021		2022		2023		2024 and Thereafter		Total
Product Revenue	$	67	$	67	$	431	$	1,923	$	2,488
Research and development revenue	1,757		—		546		—		2,303
Total revenues	$	1,824	$	67	$	977	$	1,923	$	4,791